155 results about "Onset of action" patented technology

Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.

Use of a nicotine-cellulose combination and a gum base for the preparation of a chewing gum composition for achieving a fast onset of nicotine effect after initiation of chewing the chewing gum composition by a subject. The chewing gum composition is preferably prepared by direct compression and it does not disintegrate during chewing. The invention also relates to chewing gum compositions comprising nicotine, which compositions provide a rapid release of nicotine.

The topical medicament gel formulation of the present invention includes an anesthetic, an anti-microbial, an oxidant, a nutrient, a diuretic, an opioid, an anti-emetic, an anti-seizure drug, and a non-steroidal anti-inflammatory drug (NSAID), USP in a molecular, as opposed to a salt form, as the active ingredient. Additional constituents illustratively include a skin penetration enhancer and a gelling agent. This invention deals with problems commonly associated with topical application of local medicaments such as: slow onset of action; need for occlusion; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the medicament and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

The invention discloses a medicinal composition for treating gynecological inflammation, and belongs to the field of Chinese medicament. The medicinal composition consists of collagen and / or Chinese medicaments for releasing toxin and sterilizing such as collagen and lizardtail, glabrous greenbrier rhizome, Vietnamese sophora root and the like which are prepared into a plurality of dosage forms bycombining the prior art, and is mainly used for treating vaginitis, pelvic inflammation, urethritis and cervicitis diseases. The technical scheme overcomes the defects that the prior externally-applied preparations such as lotion, gel, suppository, ointment and the like have extremely slow response, longer disease course, repeated outbreak and the like, and creatively combines and applies the collagen and the Chinese medicament, can accelerate the healing of ulcer and erosion faces caused by the inflammation, and can greatly shorten the required time for tissue repair.

The invention provides a method for preparing an environment-friendly floor board underlayer. The underlayer is prepared by firmly covering a composite catalyst material on a flaky adsorbing filter material. Only by evenly paving the environment-friendly floor board underlayer under a floor board so that the back side of the floor board is contacted with the environment-friendly floor board underlayer closely, the environment-friendly floor board underlayer can clear off harmful gases such as formaldehyde, benzene and the like and off flavor generated and released by the floor board and auxiliary materials, prevent damp and humidify, reject milden and rot, kill and inhibit bacteria, expel insects and prevent moths, increase vitamin-anions and far infrared rays in the air, and reduce the harm of dust mites and respirable particles. The environment-friendly floor board underlayer is advantageous to keep body healthy, prevent floor board form polluting, and prolong the service life of the floor board. The use is simple and convenient without professional constructions, the purification lasts without rebound, and the effect is fast and thorough; and experimental detections show that the degradation rate of the formaldehyde within 24 hours reaches 99 percent, the degradation rate of the benzene within 24 hours reaches 92 percent, the antibacterial rate is 99 percent, the mold prevention is at a zero level, the insect expelling rate is 92.8 percent, and the acute property is is actually at a nontoxic level by oral toxicity test.

The present invention provides an injection preparation containing ibuprofen and its preparation method. Said invention provides the concrete steps of its preparation method. Said ibuprofen injection preparation has high solubility and bioavailability, and its product quality is stable.

Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

The invention relates to a phosphoryl carboxylic acid propofol ester derivative which has the general formula (I). The method comprises the following steps: propofol reacts with 2-halogenated carboxylic acid and a derivative thereof by alkali to obtain corresponding ester and then the product reacts with phosphoric acid or thiophosphoric acid and the derivative thereof by dissolvent to obtain a water-soluble product or the propofol reacts with a 2-halogenated carboxylic acid phosphate ester derivative by the alkali to obtain the corresponding ester and then the ester is catalyzed, hydrogenated and salified to obtain the water-soluble product (I). The preparation method has mild reaction condition, high yield, simple operation and industrialized prospect, and a prepared oral preparation has the characteristics of high bioavailability, rapid absorption, high stability, and the like; and auxiliary materials with safety defects, such as a surface active agent, and the like can not be added into the prepared injection, thereby improving the stability of the preparation, reducing or removing injection pain, increasing the compliance of patients, overcoming the defects of propofol emulsion and having the advantage of obvious effect. The invention has the structural general formula (I).

The invention belongs to the western medicine preparation field and concretely relates to an efficient and quick effective external preparation of phentolamine which considers the volatile oil of natural plant and the extracted finished product of the volatile oil of the natural plant as a percutaneous sorbefacient and the preparation method of the external preparation. The invention selects the percutaneous sorbefacient of the natural volatile oil to prepare an external percutaneous preparation of the phentolamine of the invention by considering the phentolamine as the only curative active matter of the preparation and adding the necessary medicinal auxiliary materials. The animal experiment testifies that the invention can keep the drug usability and synchronously reduce the medicament dosage greatly and reduce the side effect to the whole body and the use cost. Compared with the prior art, the preparation can improve the percutaneous absorption of the drug dosage of the phentolamine very obviously and shortens the latent period of effecting, and the preparation has good medicament safety and can provide the patient with more satisfying curative effect.

The present invention is one kind of Chinese medicine for treating climacteric syndrome with stagnation of liver energy and vital energy and its preparation process, and belongs to the field of Chinese medicine technology. The Chinese medicine is prepared with 19 kinds of Chinese medicinal materials including bupleurum root, angelica, white peony root, tuckahoe, white atractylodes rhizome, etc; and may be prepared into medicine powder, bolus, capsule or decoction. It has excellent curative effect on climacteric syndrome with stagnation of liver energy and vital energy. It has fast and determined effect, can cure the said disease radically in high effect. As one compound Chinese medicine preparation, the medicine has proper taste and may be stored for long period.

The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient with benzyl alcohol and isopropyl alcohol. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

The invention relates to an oral instant membrane of risperidone and a preparation method thereof, thereby being used for improving the using performance of the risperidone. The technical scheme is as follows: the instant membrane comprises 2-60 parts by weight of risperidone, 25-98 parts by weight of water-soluble pharmaceutical polymer excipients, additives and 0.1-25 parts by weight of water. The oral instant membrane solves the problems that the existing risperidone is clinically difficult to swallow, is not applicable to children and elderly patients for administration and can not be conveniently taken under the situation of having no water. The oral instant membrane can be dissolved on the tongue, the hidden trouble of choking can not be happened no matter how young a baby is, the active ingredients can be absorbed sublingually and absorbed by buccal mucosa, and the onset of action is more rapid in comparison with orally disintegrating tablets. In addition, the oral instant membrane has good compliance, thereby being particularly suitable for elderly people, children and patients with difficult swallowing.

The present invention provides one kind of injection containing ketoproten and its preparation process, and features that the injection contains ketoproten, alkaline assistant and stuffing in the molar ratio between ketoproten and alkaline assistant of 1 to 1, and the weight ratio between ketoproten and stuffing of 1 to 0-10. The injection containing ketoproten is superior to traditional orally taken ketoproten preparation, and has new administration way, high product quality, high bioavailability and fast acting.

An abuse deterrent immediate release biphasic matrix solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.

The invention relates to oral double iguratimod controlled release formulation, which comprises fast release layer and slow release layer that are composed of 8-30% micronizing iguratimod crystal powder and medical findings, and the granule size of iguratimod crystal powder is 1-10 um. The effective component in fast release layer is released in short time and reaches to effective blood chemical concentration for effective action; the iguratimod in sloe release layer is released gradually and maintains effective blood medical concentration for continuous effective action. The invention overcomes shortcomings of short effective action time and a little high toxic effect.

The invention provides anti-inflammatory and analgesic flurbiprofen axetil injection and a preparation method thereof. A mixture of 0.1-10 percent (w / v) of flurbiprofen axetil, 10-20 percent (w / v) of middle chain triglyceride (MCT) and 10-20 percent (w / v) of long chain triglyceride (LCT) is contained in the prescription (wherein the proportion of MCT and LCT is 4:1-1:4). The preparation method comprises the following steps: taking 1-5 percent (w / v) of lecithin as an emulsifying agent, taking 1-5 percent (w / v) of glycerol as an isotonic agent, finally adding disodium hydrogen phosphate, citric acid and water for injection and adjusting the pH value to 4-7 to prepare flurbiprofen axetil fat emulsion injection through colostrums, homogeneity and sterilization. The injection has the beneficial effects that the anti-inflammatory and analgesic effect is taken more quickly; the accumulation of fat of a human body can be reduced, and fatty tissues and liver load can be reduced; and the injection is more suitable for critically ill patients and people with poor liver functions and has lower toxic and side effects.

The present invention provides one kind of effervescent dextro brufen tablet and its preparation process, and features that the effervescent dextro brufen tablet contains dextro brufen 1 weight portions, alkaline cosolvent 0-100 weight portions, acid disintegrant 1-8 weight portions, alkaline disintegrant 2-15 weight portions, stuffing 0-15 weight portions, adhesive 0.1-12 weight portions, corrective 0.01-0.5 weight portion, and lubricant 0.1-2 weight portions. Its preparation process includes the steps of mixing, pelletizing and tabletting. The effervescent dextro brufen tablet is superior to traditional orally taken dextro brufen preparation, can dissolve in water to form tasty solution, and has easy taking, high bioavailability, fast acting and other advantages.

The present invention discloses one kind of dextro brufen granule and its preparation process, and features that the dextro brufen granule contains dextro brufen 1 weight portions, alkaline cosolvent 0-100 weight portions, stuffing 0.1-100 weight portions, adhesive 0.1-12 weight portions, corrective 0.01-0.5 weight portion, and lubricant 0.1-2 weight portions. Its preparation process includes the steps of mixing, pelletizing and packing. The effervescent dextro brufen tablet is superior to traditional orally taken dextro brufen preparation, can dissolve in water to form tasty solution, and has easy taking, high bioavailability, fast acting and other advantages.

The invention discloses a pharmaceutical composition with the effects of hypnosis, anti-depression and anti-anxiety, and belongs to the traditional Chinese medicine field. The pharmaceutical raw materials of the pharmaceutical composition are: 6 to 40 parts by weight of Szechuan lovage rhizome and 10 to 40 parts by weight of pinellia tuber which are taken as monarch drugs; and 3 to 20 parts by weight of cape jasmine fruit or 1 to 15 parts by weight of golden thread which are taken as ministcrial drugs. The pharmaceutical composition can be prepared into any common preparation form for internal usage. The different adjuvant drugs or guide drugs can be added on the basis of the monarch drugs and the ministcrial drugs according to the different individual differences, so as to play the better efficacy. The pharmaceutical composition of the invention has the effects of hypnosis, anti-depression and anti-anxiety, the efficacy for the treatment of insomnia, depression and anxiety disorder is exact, the onset of action is fast, and the pharmaceutical composition can also be used for the treatment of insomnia, melancholia, headache, palpitation and other diseases of the traditional Chinese medicine.

The invention discloses medicinal drop pills having effects of nourishing blood, eliminating blood stasis, soothing the liver and regulating menstruation. The medicinal drop pills are prepared by the following steps of: extracting motherwort, angelica, white peony root, bupleurum root, costustoot and Szechuan lovage rhizome serving as raw materials, adding polyethylene glycol 4000, mixing uniformly and dropping. The medicinal drop pills can increase the concentration of active ingredients, so that the pills act faster effect, have exact efficacy and high safety, and can be administered in small dose; in addition, by high-temperature extraction, the medicinal drop pills effectively achieve a sterilization effect, which contributes to the quality control of preparation and the improvement of the quality of medicaments.

The invention relates to a compound Chinese medicinal preparation for treating depression. The compound Chinese medicinal preparation comprises the following Chinese medicinal raw materials in weight by percentage: 8-12 percent of root of Chinese thorowax, 8-12 percent of white paeony root, 10-14 percent of tuckahoe, 8-12 percent of angelica, 10-14 percent of pinellia ternate, 8-12 percent of officinal magnolia bark, 8-12 percent of acorus gramineus, 8-12 percent of turmeric root tuber, 13-17 percent of dragon bone, 13-17 percent of oyster and 5-7 percent of liquoric root. A preparation method of the compound Chinese medicinal preparation comprises the following steps of: cleaning the 11 medicinal materials; mixing in proportion; adding water in an amount which is 6-8 times the total weight of the medicinal materials or ethanol in an amount which is 70 percent of the volume ratio to decoct for 3 times, 50 minutes each time; combining decoction for 3 times; filtering; and concentrating to obtain liquid extract with specific gravity of 1.17 at the temperature of 60 DEG C. By adopting the conventional reparation process, the preparation can be prepared into any one pharmaceutically said formulation, such as tablets, capsules, granules, oral liquid, pills and syrup. The compound Chinese medicinal preparation for treating the depression prepared by the invention has the advantages of obvious curative effect, quick response and no adverse effect, and is suitable to be clinically applied and promoted.

Disclosed is a dispersible tablet for treating pelvic inflammation and is preparing process, wherein the tablet is prepared from right amount of flavescent sophora root, corktree bark, adzuki bean, capsule of weeping forsythia and motherwort through the steps of water boiling, condensating to thick grease, and charging right amount of auxiliary materials.

The present invention discloses one kind of medicine for treating rhinitis, and the medicine is prepared with centipeda herb 100-500 weight portions, rhubarb 50-300 weight portions, lily magnolia 50-300 weight portions, cocklebur fruit 50-300 weight portions, mint 50-300 weight portions and borneol 1-10 weight portions. The medicine has obvious systemic and local antiallergic effect and antiphlogistic effect, and is used in treating allergic rhinitis, chronic rhinitis, etc. It has fast acting, determined curative effect, high safety and less toxic side effect. The present invention also discloses the preparation process of the medicine.

The invention relates to a traditional Chinese medicine for treating cardio-cerebrovascular diseases, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 10-15 parts of Szechuan lovage rhizome, 10-15 parts of safflower, 10-15 parts of dragon's blood, 15-20 parts of radix notoginseng, 5-10 parts of radix salviae miltiorrhizae, 15-20 parts of leech, 10-15 parts of rosewood heart wood, 5-10 parts of red paeony root, 5-10 parts of kudzuvine root, 5-10 parts of ginkgo leaves, 10-15 parts of membranous milkvetch root, 5-10 parts of American ginseng, 3-5 parts of musk, 10-15 parts of twotooth achyranthes root, 15-10 parts of longstamen onion bulb, 5-10 parts of grassleaf sweelflag rhizome, 10-15 parts of largeleaf gentian root and 5-10 parts of Chinese angelica. The traditional Chinese medicine provided by the invention has scientific and reasonable formula, unique compatibility and effects of promoting blood circulation, removing blood stasis, smoothing qi and blood and the like, can dilate blood vessels, increase blood flow and improve cardio-cerebrovascular circulation, is in line with traditional Chinese medicine theory and has a significant curative effect against the cardio-cerebrovascular diseases; and furthermore, a making method of the traditional Chinese medicine is simple, convenient and easy to operate, and the traditional Chinese medicine is convenient to take, short in treatment course and rapid in onset of action, has no toxicity or side effects, can not form medicament dependence and has good economic and social benefits.

The invention discloses a sodium humate skin external preparation for promoting wound healing, which is a gel formulation, a film formulation, a film-forming formulation or an ointment formulation of sodium humate in addition with pharmaceutically-acceptable adjuvant materials. In terms of the mass fraction, the content of sodium humate is 0.1% to 20%. The sodium humate skin external preparation disclosed by the invention has strong effects of relieving the inflammation, reducing the exudation, promoting the regeneration of capillary vessels and increasing the generation of collagen, and can significantly reduce the time of wound healing and promote wound healing. The application range of sodium humate in the medicine field is increased, and the blank of sodium humate skin external preparations is filled in. The sodium humate skin external preparation is available in various forms for external application, such as a gel, a film, a film-forming agent and an ointment. The sodium humate skin external preparation has the characteristics of relatively-definite components, quick onset of action, stable property and accurate quality control, and is convenient to be used in the clinic and selected by patients.

The invention discloses a compound aerosol for quick-acting treatment of COPD, and a preparation method thereof. The compound aerosol comprises roflumilast and salbutamol. The compound aerosol combines respective characteristics of the long-acting COPD medicine roflumilast and the quick-acting COPD medicine salbutamol, and realizes rapid effectiveness and long lasting time in order to reduce the oral spray frequency of patients and reduce toxic side effects. A propellent changes from CFCs to HFC in order to eliminate destroys to the earth's ozone layer. Lecithin selected in the invention is in favor of realizing immersion and penetration of medicines to lung cells in order to improve the bioavailability and realize quick acting. Mentholum is added into a dispersant, so the patients have refreshing and comfortable feeling after administration, thereby the patients' compliance is improved.

The invention discloses an external medicament for treating hyperosteogeny and a preparation method. The external medicament is prepared from the following raw materials according to certain weight ratio: angelica, radix sileris, notopterygium incisium, rhizoma ligustici wallichii, corydalis tuber, safflower, agilawood, costus root, clove, cassia bark, rhizoma drynariae, radix paeoniae rubra, asarum, pinellia and gastrodia tuber. The external medicament prepared through technical studies has the functions of stimulating circulation to end stasis, expelling wind and removing dampness, and clearing heat and detoxication, wherein volatile oil can promote the absorption of active components. The external medicament applied to treating the hyperosteogeny not only achieves quick response, exact and lasting curative effect, difficult recurrence after healing, but also is suitable for popularization and application.

The invention belongs to the technical field of medicine, and particularly relates to an orlistat and calcium supplementing agent type organic acid calcium eutectic crystal body and a medicine composition containing the eutectic crystal body. The eutectic crystal body is prepared from orlistat and calcium supplementing agent type organic acid calcium. The eutectic crystal body has higher melting point; the requirements on the drying conditions in the raw material medicine and preparation preparing process can be reduced; the effect of inhibiting the fat absorption by the orlistat can be improved. In addition, the obtained eutectic crystal is used as raw materials for preparing an oral solid preparation; the solubility of the eutectic crystal in the oral solid preparation in water is obviously higher than that of type II orlistat in commercially available orlistat capsules; the effect taking is higher than that of the type II orlistat in commercially available orlistat capsules.